Christine Mikail Cvijic, serving as both President and Chief Financial Officer for Neurogene Inc. (NASDAQ:NGNE), has executed a series of stock sales totaling 4,800 shares of the company's common equity. The transactions, spanning July 1 through July 2, 2026, resulted in proceeds of approximately $166,586. These divestments were carried out within a price range of $34.059 to $35.227 per share. The current market valuation places the stock at $35.34, a level that sits in close proximity to its 52-week peak of $37.27. This pricing reflects a substantial 79% appreciation over the trailing twelve-month period.
According to valuation metrics derived from InvestingPro analysis, the stock is currently positioned above its estimated Fair Value, a classification that places it among companies categorized as overvalued. For subscribers of InvestingPro, this analysis is part of a broader suite that includes 15 additional exclusive tips and comprehensive financial metrics specific to NGNE.
The sales were executed in accordance with a Rule 10b5-1 trading plan, a pre-arranged framework that Ms. Cvijic initially adopted on August 18, 2025. The specific shares sold in this transaction were held jointly by Ms. Cvijic and her spouse, David Cvijic. The transactional breakdown reveals distinct pricing tiers across the two-day window. On July 1, Ms. Cvijic disposed of 739 shares at a weighted average price of $34.059, with individual trade executions ranging from $34.005 to $34.095. The following day, July 2, saw the sale of an additional 2,531 shares at a weighted average price of $34.579, with prices for these specific transactions ranging from $34.05 to $34.99. A subsequent tranche of 1,530 shares was also sold on July 2, achieving a weighted average price of $35.227, with individual sales occurring between $35.11 and $35.255.
Post-transaction, Ms. Cvijic's direct holdings in Neurogene common stock stand at 88,840 shares. This total inventory includes several tranches of restricted stock units (RSUs) with defined vesting schedules. Specifically, 10,635 RSUs are scheduled to vest on March 13, 2027. An additional 13,533 RSUs will vest in equal annual installments on March 26, 2027, and March 26, 2028. Furthermore, 22,000 RSUs are set to vest in equal installments on February 20 of 2027, 2028, and 2029. Of the remaining shares in her direct portfolio, 4,800 are held jointly with her spouse.
Contextual market data indicates Neurogene's stock closed at 35.34, reflecting a gain of 1.460 (4.31%) at 15:59:59 USD. After-hours trading showed a decline to 34.78, representing a drop of 0.560 (1.58%) at 17:44:46. This volatility occurs against the backdrop of recent corporate actions. Neurogene recently announced the pricing of a public offering comprising 3.5 million shares of common stock at $30 per share, a move designed to raise approximately $125 million in gross proceeds. The company also issued pre-funded warrants allowing for the purchase of up to 666,666 additional shares, with an exercise price set at a nominal value.
This financing activity follows the release of positive Phase 1/2 trial data for NGN-401, a treatment for Rett syndrome. The data prompted Leerink to raise its stock price target to $77 and increase its probability of success estimate for the treatment from 60% to 70%. Despite these positive clinical developments, Neurogene's stock experienced a decline following the public offering announcement. In the broader biotech sector, Citizens reiterated its Market Outperform rating for Taysha Gene Therapies, maintaining a price target of $11.00. Investors are closely monitoring Taysha's TSHA-102 program, with pivotal data and regulatory feedback anticipated in 2027. These developments underscore the dynamic interplay between clinical milestones, capital raising, and market valuation in the biotechnology sector.